Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new treatment.

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Researchers have been working on ways to improve prostate cancer diagnosis and deaths for years. Being one of the most common ...